{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-002093","form_type":"8-K","ticker":"PASG","cik":"0001787297","company_name":"Passage BIO, Inc.","filed_at":"2025-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.863009+00:00","generated_at":"2026-05-25T15:00:26.727484+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Passage Bio reports FY2024 net loss $64.8M, cash $76.8M; PBFT02 shows durable PGRN elevation in FTD-GRN","bullets":["Cash, cash equivalents and marketable securities $76.8M as of Dec 31, 2024, down from $114.3M; runway extended into 1Q 2027.","Net loss of $12.7M ($0.20 per share) for Q4 2024 vs $16.8M ($0.30) a year ago; full year net loss $64.8M ($1.07) vs $102.1M.","Dose 1 PBFT02 increased CSF PGRN from <3 ng/mL to 13-27 ng/mL at 6 months (n=4) and 22-34 ng/mL at 12 months (n=2).","Plasma NfL levels 13% lower vs baseline at 12 months vs expected 29% annual increase from natural history data.","First FTD-GRN patient enrolled with Dose 2 (50% lower); plan to report 12-month data and interim Dose 2 data in 2H 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-002093","json":"https://secwatch.observer/filing/0001558370-25-002093.json","markdown":"https://secwatch.observer/filing/0001558370-25-002093.md","text":"https://secwatch.observer/filing/0001558370-25-002093.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787297/000155837025002093/0001558370-25-002093-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787297/000155837025002093/pasg-20250304x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T15:00:26.727484+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}